Parvoviruses-tools to fine-tune anticancer immune responses

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1417-1419

  Grekova, Svitlana P ^a   Rommelaere, Jean ^a   Raykov, Zahari ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Immune response; Oncolytic viruses; Parvoviruses

Indexed keywords

ADJUVANT; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; GEMCITABINE; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIOSARCOMA; ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL KILLING; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG POTENTIATION; EXPERIMENTAL MODEL; GLIOMA; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; LUNG METASTASIS; NONHUMAN; NOTE; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PARVOVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE; TROPISM; TUMOR IMMUNITY; VIRION;

EID: 84884693015     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21097     Document Type: Note

References (10)

1. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010; 21:185-95.
2. Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, et al. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol Ther 2011; 10:1280-9.
3. Grekova SP, Raykov Z, Zawatzky R, Rommelaere J, Koch U. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Cancer Gene Ther 2012.
4. Giese NA, Raykov Z, DeMartino L, Vecchi A, Sozzani S, Dinsart C, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002; 9:432-42.
5. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009; 15:511-9.
6. Raykov Z, Savelyeva L, Balboni G, Giese T, Rommelaere J, Giese NA. B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J Virol 2005; 79:3517-24.
7. Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep 2007; 17:1493-9.
8. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 2005; 16:996-1005.
9. Bhat R, Dempe S, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer 2011; 128:908-19.
10. Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer 2008; 122:2880-4.